Success Metrics

Clinical Success Rate
89.3%

Based on 25 completed trials

Completion Rate
89%(25/28)
Active Trials
2(6%)
Results Posted
36%(9 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_1
2
6%
Ph phase_4
2
6%
Ph early_phase_1
1
3%
Ph phase_2
8
22%
Ph phase_3
2
6%
Ph not_applicable
21
58%

Phase Distribution

3

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution36 total trials
Early Phase 1First-in-human
1(2.8%)
Phase 1Safety & dosage
2(5.6%)
Phase 2Efficacy & side effects
8(22.2%)
Phase 3Large-scale testing
2(5.6%)
Phase 4Post-market surveillance
2(5.6%)
N/ANon-phased studies
21(58.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.6%

25 of 31 finished

Non-Completion Rate

19.4%

6 ended early

Currently Active

2

trials recruiting

Total Trials

36

all time

Status Distribution
Active(2)
Completed(25)
Terminated(6)
Other(3)

Detailed Status

Completed25
Terminated3
Withdrawn3
unknown3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
2
Success Rate
89.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.8%)
Phase 12 (5.6%)
Phase 28 (22.2%)
Phase 32 (5.6%)
Phase 42 (5.6%)
N/A21 (58.3%)

Trials by Status

completed2569%
terminated38%
withdrawn38%
active_not_recruiting13%
recruiting13%
unknown38%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT01881048Early Phase 1

Window of Opportunity Study Targeting the Inflammatory Milieu

Completed
NCT01248130Phase 2

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Terminated
NCT02176902Not Applicable

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Active Not Recruiting
NCT03649698Not Applicable

Exercise and Nutrition for Healthy AgeiNg

Recruiting
NCT03120299Phase 4

The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

Completed
NCT01027143Phase 2

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

Completed
NCT05924139Not Applicable

Omega-3 Fatty Acid Supplementation to Enhance Performance

Completed
NCT02831582Not Applicable

Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

Completed
NCT01821833Not Applicable

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Completed
NCT03006016Not Applicable

Preoperative Omega-3 Polyunsaturated Fatty Acids in Morbidly Obese to Reduce Liver Volume and Steatosis

Completed
NCT04005612Not Applicable

Effect of Vitamin d and Omega 3 on Osteocalcin

Completed
NCT01869764Phase 2

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Completed
NCT00644423Not Applicable

Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)

Completed
NCT02150525Phase 2

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Completed
NCT00996749Not Applicable

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Withdrawn
NCT00579436Not Applicable

Effects of Fish Oils on Inflammation and Insulin Resistance

Completed
NCT02352779Not Applicable

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors

Completed
NCT02204410Phase 4

Omega-3 Supplementation to ADHD Medication in Children

Completed
NCT00627276Not Applicable

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

Completed
NCT01385137Phase 3

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
36